Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug Candidate
Jaguar concurrently receives
Deal brings in immediate non-dilutive capital to fund pipeline of plant-based prescription drug candidates of Jaguar's
"We are pleased to enter into this agreement with Atlas Sciences, as it supports our strategy to bring in non-dilutive capital to fund Napo's plant-based R&D pipeline," said
NP-500 is a plant-based drug product candidate for treatment of type II diabetes and insulin-resistance syndrome in humans. Derived from a plant found in
"We are delighted to move forward another plant-based therapeutic agent that has been utilized for centuries as part of traditional medicine,"
According to data from the
Under the terms of the license, Jaguar is obligated to initiate a proof of concept Phase 2 study of NP-500 under an investigational new drug ("IND") application with the
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy, and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's efforts to forge additional non-dilutive funding partnerships to advance key potential pipeline indications into development, commercialization, and access outside the
1 The already staggering insulin shortage could get worse,
2 Meigs, J.B. Epidemiology of the insulin resistance syndrome. Curr Diab Rep 3, 73-79 (2003)